血清lncRNA牛磺酸上调基因1、lncRNA肺腺癌转移相关转录子1的表达水平在帕金森病患者严重程度及早期诊断中的意义  

The significance of serum lncRNA taurine upregulated gene 1 and lncRNA metastasis-associated lung adenocarcinoma transcript 1 expression levels in the severity and early diagnosis of patients with Parkinson's disease

作　　者：李金燕 朱可 樊新红 李建瑞 李艳艳 刘晨阳 Li Jinyan;Zhu Ke;Fan Xinhong;Li Jianrui;Li Yanyan;Liu Chenyang(Department of Neurology,Norinco General Hospital,Shaanxi,Xi'an 710000,China;不详)

机构地区：[1]兵器工业总医院神经内科,西安710000 [2]兵器工业总医院心脑血管重症医学科,西安710000 [3]西安高新医院神经内科,710075

出　　处：《疑难病杂志》2025年第4期450-455,共6页Chinese Journal of Difficult and Complicated Cases

基　　金：陕西省卫生健康科研项目(2020D0029)。

摘　　要：目的探讨血清lncRNA牛磺酸上调基因1(lncRNA TUG1)和lncRNA肺腺癌转移相关转录子1(lncRNA MALAT1)表达水平与帕金森病(PD)严重程度的关系及对早期诊断的意义。方法选取2022年1月—2024年1月兵器工业总医院神经内科收治的PD患者120例作为观察组,根据Hoehn-Yahr(H-Y)分级将观察组患者分为早期亚组(1~2.5级)46例和中晚期亚组(3~5级)74例,另外选择同期体检的健康志愿者110例为健康对照组。检测各组血清lncRNA TUG1和lncRNA MALAT1的表达水平;采用Spearman分析两者与PD病情严重程度的相关性;比较不同严重程度PD患者临床资料的差异;多因素Logistic回归分析PD患者病情严重程度的影响因素;绘制受试者工作特征(ROC)曲线检测血清lncRNA TUG1和lncRNA MALAT1对PD患者病情的预测价值。结果观察组患者血清lncRNA TUG1和lncRNA MALAT1水平高于健康对照组(t/P=15.668/<0.001,60.822/<0.001),且中晚期亚组水平高于早期亚组(t/P=6.670/<0.001,17.793/<0.001),两者水平与病情严重程度呈显著正相关(r_(s)/P=0.608/<0.001、0.712/<0.001);中晚期亚组患者简易智能精神状态检查量表(MMSE)评分、帕金森病综合量表评分(UPDRS)均高于早期亚组(t/P=5.116/<0.001、25.014/<0.001);MMSE评分高、UPDRS评分高、lncRNA TUG1高、lncRNA MALAT1高为影响PD患者严重程度的独立危险因素[OR(95%CI)=1.364(1.125~1.655)、1.812(1.472~2.311)、4.543(1.322~7.890)、5.318(1.773~9.034)]。血清lncRNA TUG1、lncRNA MALAT1单独及二者联合预测PD患者病情严重程度的曲线下面积(AUC)分别为0.770、0.846、0.894,二者联合预测的AUC优于其单项检测(Z/P=2.065/0.037,3.028/0.026)。结论血清lncRNA TUG1和lncRNA MALAT1水平与PD发病及病情进展关系密切,检测两种指标水平对于预测PD早期发病和病情发展意义重大。Objective To investigate the relationship between the expression levels of serum lncRNA taurine upregulated gene 1(lncRNA TUG1)and lncRNA metastasis-associated lung adenocarcinoma transcript 1(lncRNA MALAT1)and the severity of Parkinson's disease(PD)and its significance for early diagnosis.Methods One hundred and twenty PD patients admitted to the Department of Neurology,Norinco General Hospital from January 2022 to January 2024 were selected as the observation group.According to Hoehn-Yahr(H-Y)classification,the patients in the observation group were divided into early subgroup(gradeⅠ-Ⅱ)46 cases and middle-late subgroup(gradeⅢ-Ⅴ)74 cases.In addition,110 healthy volunteers who underwent physical examination during the same period were selected as the healthy control group.The expression levels of serum lncRNA TUG1 and lncRNA MALAT1 in each group were detected,and the correlation between them and the severity of PD was analyzed by Spearman;the clinical data of PD patients with different severity were compared,multivariate Logistic analysis was used to analyze the influencing factors affecting the severity of PD patients,the predictive value of serum lncRNA TUG1 and lncRNA MALAT1 in PD patients was detected by receiver operating curve(ROC).Results The levels of serum lncRNA TUG1 and lncRNA MALAT1 in the observation group were higher than those in the healthy control group(t/P=15.668/<0.001,60.822/<0.001),and the levels in the middle-late subgroup were higher than those in the early subgroup(t/P=6.670/<0.001,17.793/<0.001),the levels of the two were significantly positively correlated with the severity of the disease(r/P=0.608/<0.001,0.712<0.001);the scores of Mini-Mental State Examination(MMSE)and Unified Parkinson's Disease Rating Scale(UPDRS)in the middle-late subgroup were higher than those in the early subgroup(t/P=5.116/<0.001,25.014/<0.001);High MMSE score,high UPDRS score,high lncRNA TUG1 and high lncRNA MALAT1 were independent risk factors affecting the severity of PD patients[OR(95%)CI=1.364(1.125-

关 键 词：帕金森病 lncRNA牛磺酸上调基因1 lncRNA肺腺癌转移相关转录子1 严重程度 诊断预测价值 

分 类 号：R742.5[医药卫生—神经病学与精神病学]